Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AZYO | Class A Common Stock | Award | +70.1K | +138.81% | 121K | Sep 21, 2023 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AZYO | Warrants (rights to buy) | Award | +105K | 105K | Sep 21, 2023 | Class A Common Stock | 105K | $1.43 | Direct | F1, F3 |
Id | Content |
---|---|
F1 | The reported securities are included within the 70,053 Units purchased by the reporting person for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock and one warrant to purchase one and one-half shares of Class A Common Stock. |
F2 | Includes 901 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan. |
F3 | The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028. |